New York, NY (June 8, 2018) – The U.S. Food and Drug Administration (FDA) announced today it has approved the use of venetoclax (VENCLEXTA) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with…
New York, NY (May 1, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (KYMRIAH ®) for the treatment of large B-cell lymphoma after two or…
New York, NY (March 20, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (ADCETRIS®) in combination with chemotherapy for the treatment of adults with previously untreated Stage III or IV classical…
New York, NY (October 19, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of axicabtagene ciloleucel (YescartaTM, Kite, a Gilead Company) to treat patients with large B-cell lymphoma who have relapsed or have…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of obinutuzumab (Gazyva®) to treat patients with previously untreated advanced follicular lymphoma (FL). Under the new indication, patients with stage II…
New York, NY (November 9, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (ADCETRIS®) to treat patients with certain types of cutaneous T-cell lymphoma (CTCL) who have received at least one…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of acalabrutinib (CALQUENCE) to treat patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The Bruton…
New York, NY (September 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of copanlisib to treat patients with relapsed indolent follicular lymphoma (FL). The PI3K dual-isoform inhibitor, developed by Bayer, has been…
New York, NY (August 3, 2017) – New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (Imbruvica ®) to treat patients with chronic graft versus host disease (cGVHD) who have…
New York, NY (June 5, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of subcutaneous rituximab (Rituxan ®) to treat patients with previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL),…